Amylyx Pharmaceuticals Inc. (AMLX): Citi sees "a lot of positivity" in the pipeline and recommends buying the stock!

The pipeline of Amylyx Pharmaceuticals Inc. (AMLX) includes several promising candidates currently in various clinical phases. Avexitide, a potential "First-in-Class" GLP-1 receptor antagonist, is currently being investigated in a pivotal Phase 3 study named LUCIDITY for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism. Recruitment for LUCIDITY is expected to be completed by 2025, with topline data anticipated in the first half of 2026. Another key candidate is AMX0035, which showed positive long-term results from the Phase 2 HELIOS...